MET and hepatocellular carcinoma: Interestingly, two highly selective c-Met inhibitors that have been approved by the FDA for the indication of NSCLC harboring the METex14 skipping mutation, tepotinib and capmatinib, have shown promising efficacy in early clinical trials in HCC.88–90